Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Bioventus Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-56.2% vs price
Base Case (Median)
17.5% vs price
Bull Case (75th pct.)
52.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $21.57 | 44.6% | High (40%) |
| PE Comparable | $17.53 | 17.5% | Medium (25%) |
| Growth Trajectory DCF | $44.07 | 195.4% | Medium (20%) |
| Graham Number | $6.86 | -54.1% | Medium (40%) |
| EV/EBITDA | $6.21 | -58.4% | Medium (20%) |
| EV/FCF | $23.95 | 60.5% | Medium (20%) |
| Earnings Power Value | $5.34 | -64.2% | Medium (50%) |
Based on 7 out of 7 methods, BVS appears fairly valued at the current price of $14.92. The base case fair value of $17.53 implies 17.5% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.